Long term efficacy of paroxetine in major depression

A study with plasma levels

Massimo Carlo Mauri, Valerio Laini, Antonella Bitetto, Luigi Boscati, Marta Scalvini, Lorenzo Mapelli, Renata Rudelli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Depressive disorders can be regarded as recurrent and chronic conditions that may reduce the quality of life and work output of patients. Data on the long-term efficacy of paroxetine appear to indicate that it is an effective maintenance treatment. Our aim was to measure paroxetine concentrations in plasma in order to optimize its clinical efficacy and tolerability during long-term treatment. We studied 35 patients aged 23-70 years, suffering from Major Depressive Disorder (recurrent). These patients received 10-50 mg of paroxetine once a day for one year; they were evaluated at baseline, after 2 weeks and then after 1, 2, 6, 9 and 12 months by BPRS, HRS-D and HRS-A rating scales, and at the same time, any side-effects were assessed and samples for paroxetine plasma determination were also collected. Results confirmed the efficacy and tolerability of paroxetine for long-term treatment. We observed a curvilinear relationship between plasma paroxetine levels and improvement on the HRS-D with greater clinical amelioration at plasma levels between 20 and 70 ng/ml.

Original languageEnglish
Pages (from-to)115-119
Number of pages5
JournalInternational Journal of Psychiatry in Clinical Practice
Volume3
Issue number2
Publication statusPublished - Jun 1999

Fingerprint

Paroxetine
Depression
Major Depressive Disorder
Depressive Disorder
Therapeutics
Quality of Life

Keywords

  • Major depression
  • Paroxetine
  • Plasma levels

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Mauri, M. C., Laini, V., Bitetto, A., Boscati, L., Scalvini, M., Mapelli, L., & Rudelli, R. (1999). Long term efficacy of paroxetine in major depression: A study with plasma levels. International Journal of Psychiatry in Clinical Practice, 3(2), 115-119.

Long term efficacy of paroxetine in major depression : A study with plasma levels. / Mauri, Massimo Carlo; Laini, Valerio; Bitetto, Antonella; Boscati, Luigi; Scalvini, Marta; Mapelli, Lorenzo; Rudelli, Renata.

In: International Journal of Psychiatry in Clinical Practice, Vol. 3, No. 2, 06.1999, p. 115-119.

Research output: Contribution to journalArticle

Mauri, MC, Laini, V, Bitetto, A, Boscati, L, Scalvini, M, Mapelli, L & Rudelli, R 1999, 'Long term efficacy of paroxetine in major depression: A study with plasma levels', International Journal of Psychiatry in Clinical Practice, vol. 3, no. 2, pp. 115-119.
Mauri, Massimo Carlo ; Laini, Valerio ; Bitetto, Antonella ; Boscati, Luigi ; Scalvini, Marta ; Mapelli, Lorenzo ; Rudelli, Renata. / Long term efficacy of paroxetine in major depression : A study with plasma levels. In: International Journal of Psychiatry in Clinical Practice. 1999 ; Vol. 3, No. 2. pp. 115-119.
@article{c84e6d3c305246a68e97414838ff8b68,
title = "Long term efficacy of paroxetine in major depression: A study with plasma levels",
abstract = "Depressive disorders can be regarded as recurrent and chronic conditions that may reduce the quality of life and work output of patients. Data on the long-term efficacy of paroxetine appear to indicate that it is an effective maintenance treatment. Our aim was to measure paroxetine concentrations in plasma in order to optimize its clinical efficacy and tolerability during long-term treatment. We studied 35 patients aged 23-70 years, suffering from Major Depressive Disorder (recurrent). These patients received 10-50 mg of paroxetine once a day for one year; they were evaluated at baseline, after 2 weeks and then after 1, 2, 6, 9 and 12 months by BPRS, HRS-D and HRS-A rating scales, and at the same time, any side-effects were assessed and samples for paroxetine plasma determination were also collected. Results confirmed the efficacy and tolerability of paroxetine for long-term treatment. We observed a curvilinear relationship between plasma paroxetine levels and improvement on the HRS-D with greater clinical amelioration at plasma levels between 20 and 70 ng/ml.",
keywords = "Major depression, Paroxetine, Plasma levels",
author = "Mauri, {Massimo Carlo} and Valerio Laini and Antonella Bitetto and Luigi Boscati and Marta Scalvini and Lorenzo Mapelli and Renata Rudelli",
year = "1999",
month = "6",
language = "English",
volume = "3",
pages = "115--119",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Long term efficacy of paroxetine in major depression

T2 - A study with plasma levels

AU - Mauri, Massimo Carlo

AU - Laini, Valerio

AU - Bitetto, Antonella

AU - Boscati, Luigi

AU - Scalvini, Marta

AU - Mapelli, Lorenzo

AU - Rudelli, Renata

PY - 1999/6

Y1 - 1999/6

N2 - Depressive disorders can be regarded as recurrent and chronic conditions that may reduce the quality of life and work output of patients. Data on the long-term efficacy of paroxetine appear to indicate that it is an effective maintenance treatment. Our aim was to measure paroxetine concentrations in plasma in order to optimize its clinical efficacy and tolerability during long-term treatment. We studied 35 patients aged 23-70 years, suffering from Major Depressive Disorder (recurrent). These patients received 10-50 mg of paroxetine once a day for one year; they were evaluated at baseline, after 2 weeks and then after 1, 2, 6, 9 and 12 months by BPRS, HRS-D and HRS-A rating scales, and at the same time, any side-effects were assessed and samples for paroxetine plasma determination were also collected. Results confirmed the efficacy and tolerability of paroxetine for long-term treatment. We observed a curvilinear relationship between plasma paroxetine levels and improvement on the HRS-D with greater clinical amelioration at plasma levels between 20 and 70 ng/ml.

AB - Depressive disorders can be regarded as recurrent and chronic conditions that may reduce the quality of life and work output of patients. Data on the long-term efficacy of paroxetine appear to indicate that it is an effective maintenance treatment. Our aim was to measure paroxetine concentrations in plasma in order to optimize its clinical efficacy and tolerability during long-term treatment. We studied 35 patients aged 23-70 years, suffering from Major Depressive Disorder (recurrent). These patients received 10-50 mg of paroxetine once a day for one year; they were evaluated at baseline, after 2 weeks and then after 1, 2, 6, 9 and 12 months by BPRS, HRS-D and HRS-A rating scales, and at the same time, any side-effects were assessed and samples for paroxetine plasma determination were also collected. Results confirmed the efficacy and tolerability of paroxetine for long-term treatment. We observed a curvilinear relationship between plasma paroxetine levels and improvement on the HRS-D with greater clinical amelioration at plasma levels between 20 and 70 ng/ml.

KW - Major depression

KW - Paroxetine

KW - Plasma levels

UR - http://www.scopus.com/inward/record.url?scp=0032865188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032865188&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 115

EP - 119

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 2

ER -